Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapy

Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapy - Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008198

Enrollment

200

Registered

2012-06-19

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

IL28B gene major and relapse of previous treatment/first treatment patient with intrahepatic IFN stimulating gene index&lt

3.5: 12 week Peg-IFN-alfa-2a/Ribavirin/Telaprevir therapy following 12week Peg-IFN-alfa-2a/Ribavirin therapy IL28B gene major and non-response of previous treatment/first treatment patient with intrah

3.5: 12 week Peg-IFN-alfa-2a/Ribavirin/Telaprevir therapy following 12week Peg-IFN-alfa-2a/Ribavirin therapy IL28B gene minor and relapse of previous treatment/first treatment patient with intrahepati

3.5: 12 week Peg-IFN-alfa-2a/Ribavirin/Telaprevir therapy following 36 week Peg-IFN-alfa-2a/Ribavirin therapy IL28B gene minor and non-response of previous treatment/first treatment patient with intra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C serogroup1 and high viral load

Exclusion criteria

Exclusion criteria: contraindication of Peg-IFN/Ribavirin/Telaprevir therapy

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactTetsuro Shimakami

Kanazawa University University Hospital

shimakami@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026